HRMY 34.97 Harmony Biosciences Holdings, Inc.
| Range: | 18.611-40.6 | Vol Avg: | 432326 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 0.73 | Cap: | 1.98B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Aug 19 2020 | Empoloyees: | 246 | ||
| CUSIP: | 413197104 | CIK: | 0001802665 | ISIN: | US4131971040 | Country: | US |
| CEO: | Dr. Jeffrey M. Dayno M.D. | Website: | https://www.harmonybiosciences.com | ||||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Stock Details
Positive 0.27
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it...
accesswire.com·Thu Oct 10 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow